ALGS Aligos Therapeutics, Inc.

Overview and Growth

Aligos Therapeutics, Inc. generated $2.19M of revenue in fiscal 2025, with net loss of $24.19M and an operating cash outflow of $82.50M. Revenue of $2.19M sets the scale for evaluating how effectively sales translated into profit and cash during the year. Compared with $3.61M in fiscal 2024, revenue decreased 39.5%, a top-line contraction that reduced operating scale. On a per-share basis, diluted EPS was -$2.45, which connects the reported earnings outcome with the company’s diluted share count. The diluted weighted-average share count was 9.88M, linking total earnings with the per-share result received by shareholders. Diluted shares moved 57.8% from 6.26M in fiscal 2024, leaving the current share base higher year over year. The company employed $88.53M of total assets, the balance-sheet base supporting its current operating and cash-flow results. Revenue equaled 0.02x of total assets, indicating how much reported top-line activity the company produced relative to its period-end asset base.

Profitability

Operations produced a $87.98M operating loss before non-operating and tax effects. The company ended the period with a net loss of $24.19M, extending the operating result through all remaining items. The company reported negative EBITDA of $87.06M, adding a pre-interest, tax, depreciation, and amortization view of the operating shortfall. Before income taxes, the company recorded a loss of $23.88M, bridging the operating result to the final net loss. Income tax expense totaled $314.00K, providing the reported tax component that separates pretax and after-tax earnings. Relative to period-end equity, the net loss represented 45.2%. The net loss equaled 27.3% of period-end assets, showing the deficit relative to the asset base. Compared with a $131.21M net loss in fiscal 2024, the current loss improved to $24.19M.

Liquidity and Capital Structure

The company held $88.53M of assets against $34.99M of liabilities and $53.55M of equity, revealing how the asset base was financed. The near-term balance sheet paired $82.86M of current assets with $21.23M of current liabilities at the reporting date. At 3.9x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. Reported cash and equivalents were $18.30M, separating immediately recognizable cash resources from the rest of the current-asset base. Cash and equivalents represented 86.2% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. Equity equaled 60.5% of assets, showing the shareholder-capital layer within the company’s balance sheet. Liabilities represented 39.5% of total assets, quantifying the liability-funded share of the company’s resource base. Cash and equivalents equaled 20.7% of total assets, showing the liquid cash component within the company’s broader resource base. Total assets were 26.3% higher than fiscal 2024 assets of $70.09M, measuring the company’s own balance-sheet change. Cash and equivalents were 50.5% lower than fiscal 2024 cash of $37.00M, showing the year-over-year change in liquid resources.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $82.50M, rather than cash generation from operations. Compared with a $80.74M operating cash outflow in fiscal 2024, the current outflow increased to $82.50M.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.